New York Representative Christopher Collins sent a letter to House Speaker Nancy Pelosi on September 30 announcing that he is resigning from his position in the House.
The contentious congressman is currently facing insider trading charges that he was indicted on in August 2018 alongside his son Cameron Collins and his son’s fiancee’s father, Stephen Zarsky.
Collins is expected to plead guilty on these charges as well as charges that claim he lied to the FBI in an attempt to coverup the scheme involving Innate Immunotherapeutics.
Collins first made headlines as the first member of Congress to formally endorse Donald Trump for president.
With a wide range of investments and assets, Collins is worth a hefty amount as he faces trial — even if the exact amount is still somewhat elusive.
Collins was a majority shareholder and board member of Innate Immunotheraputics as well as a major investor in both Volland Electric Corporation and ZeptoMetrix Corporation in 2015, when his last reported net worth was $66.5 million.
He invested $33.7 million to the pharmaceuticals/health industry at that time and his estimated asset valuation in Innate and Volland was a combined $30 million.
Collins' most recent financial disclosures (in 2018) include buying shares in Cocooon Development LLC in the $250,001to $500,00 financial bracket as well as selling shares of Innate Immunotherapeutics worth between 15,001 and $50,000 and holdings in Emergent Capital and ChemBio Diagnostics worth between worth between $1,001 and $15,000 and $500,001 and $1 million, respectively.
It is now estimated that Collins net worth is around $50 million, per movement of his shares and holdings in the past four years.